Sign Up
Stories
IVIg Offers Hope for 20-Year Remission in PV
Share
Advancements in Cancer Treatment and Mar...
Advancements in Immunotherapy for Neurol...
Advancements in Lymphoma Treatments
ANJESO Drug Insight and Market Forecast
BioInvent's Collaboration for Lymphoma T...
Biopharma Appoints Industry Veteran
Overview
API
Researchers at Tufts University School of Medicine and Sorbonne Université have shown a 20-year clinical and serological remission in patients with pemphigus vulgaris using IVIg therapy. The study suggests IVIg may restore immune balance and tolerance, offering hope for long-term remission. Further research is needed to understand immune tolerance mechanisms in autoimmune diseases.
Ask a question
How might this research impact the treatment landscape for other autoimmune diseases?
What are the ethical considerations and potential risks associated with using IVIg therapy for autoimmune diseases?
What are the potential implications of restoring immune balance and tolerance in autoimmune diseases?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Oct 2023
Nov 2023
Dec 2023
Jan 2024
Coverage